Active Lyme disease of the central nervous system cannot be detected with an ELISpot test.

The societal costs of Lyme disease have been determined for the Netherlands for the first time. The disease appears to cost nearly EUR 20 million each year.

Lyme disease can cause a variety of complaints in patients. Laboratory tests for the disease can support medical practitioners in making a diagnosis but are not necessarily conclusive.

The application of nanotechnology to design and produce medical devices is increasing. RIVM provides an overview of nanotechnology enabled medical devices.

The Netherlands is the first country where the burden of disease due to Lyme disease has been determined.

By combining the available international knowledge, the method to assess the extent to which consumers are exposed to chemical substances via everyday products such as paint, cleaning agents and co

RIVM is developing methods to identify new and emerging risks of chemical substances to workers, consumers and the environment.